Fieldview Capital Management LLC Takes $2.06 Million Position in Agilent Technologies, Inc. $A

Fieldview Capital Management LLC purchased a new stake in shares of Agilent Technologies, Inc. (NYSE:A) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 15,123 shares of the medical research company’s stock, valued at approximately $2,058,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Gabelli Funds LLC lifted its holdings in shares of Agilent Technologies by 1.1% during the third quarter. Gabelli Funds LLC now owns 6,620 shares of the medical research company’s stock valued at $850,000 after purchasing an additional 74 shares in the last quarter. Fiduciary Trust Co lifted its holdings in shares of Agilent Technologies by 1.6% during the third quarter. Fiduciary Trust Co now owns 4,931 shares of the medical research company’s stock valued at $633,000 after purchasing an additional 77 shares in the last quarter. NorthCrest Asset Manangement LLC lifted its holdings in shares of Agilent Technologies by 1.6% during the fourth quarter. NorthCrest Asset Manangement LLC now owns 5,082 shares of the medical research company’s stock valued at $726,000 after purchasing an additional 79 shares in the last quarter. Freestone Capital Holdings LLC lifted its holdings in shares of Agilent Technologies by 2.0% during the fourth quarter. Freestone Capital Holdings LLC now owns 4,218 shares of the medical research company’s stock valued at $574,000 after purchasing an additional 84 shares in the last quarter. Finally, Cibc World Market Inc. lifted its holdings in shares of Agilent Technologies by 0.3% during the third quarter. Cibc World Market Inc. now owns 29,076 shares of the medical research company’s stock valued at $3,732,000 after purchasing an additional 85 shares in the last quarter.

Agilent Technologies Stock Performance

Shares of A opened at $129.76 on Friday. The company has a quick ratio of 1.62, a current ratio of 2.10 and a debt-to-equity ratio of 0.43. The business has a 50-day simple moving average of $120.24 and a two-hundred day simple moving average of $127.86. The stock has a market cap of $36.65 billion, a price-to-earnings ratio of 26.06, a PEG ratio of 2.31 and a beta of 1.26. Agilent Technologies, Inc. has a 52 week low of $108.35 and a 52 week high of $160.27.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Wednesday, May 27th. The medical research company reported $1.49 EPS for the quarter, topping analysts’ consensus estimates of $1.41 by $0.08. The business had revenue of $1.84 billion during the quarter, compared to analysts’ expectations of $1.80 billion. Agilent Technologies had a return on equity of 24.33% and a net margin of 19.55%.The business’s quarterly revenue was up 10.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.31 earnings per share. Agilent Technologies has set its FY 2026 guidance at 6.000-6.100 EPS and its Q3 2026 guidance at 1.480-1.500 EPS. On average, analysts expect that Agilent Technologies, Inc. will post 6 EPS for the current year.

Agilent Technologies Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 22nd. Investors of record on Tuesday, June 30th will be given a dividend of $0.255 per share. The ex-dividend date is Tuesday, June 30th. This represents a $1.02 annualized dividend and a dividend yield of 0.8%. Agilent Technologies’s dividend payout ratio (DPR) is currently 20.48%.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. HSBC lowered their target price on Agilent Technologies from $180.00 to $165.00 and set a “buy” rating on the stock in a report on Wednesday, June 3rd. TD Cowen increased their target price on Agilent Technologies from $147.00 to $155.00 and gave the company a “buy” rating in a report on Thursday, May 28th. Piper Sandler assumed coverage on Agilent Technologies in a report on Thursday. They issued a “neutral” rating and a $150.00 target price on the stock. Royal Bank Of Canada assumed coverage on Agilent Technologies in a report on Wednesday, May 27th. They issued an “outperform” rating and a $153.00 target price on the stock. Finally, Wall Street Zen raised Agilent Technologies from a “hold” rating to a “buy” rating in a report on Saturday, May 30th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $160.93.

Agilent Technologies Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.